Ebola virus vaccines: An overview of current approaches

Expert Review of Vaccines

Volumn 13, Issue 4, 2014, Pages 521-531

  Marzi, Andrea ^a   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Vaccine

Indexed keywords

EBOLA VACCINE; VIRUS VECTOR;

BIOLOGICAL WARFARE; CENTRAL AFRICA; DISEASE COURSE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HUMAN; INFECTION PREVENTION; NONHUMAN; PRIMATE; PRIMATE MODEL; PRIORITY JOURNAL; REVIEW; VACCINATION;

AFRICA, CENTRAL; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; DRUG DISCOVERY; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; PRIMATES; SURVIVAL ANALYSIS;

EID: 84896471849     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.885841     Document Type: Review

References (77)

1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editor. Fields virology. Lippincott Williams Philadelphia, PA, USA: 2006. p. 1409-48
2. Outbreak news. Ebola haemorrhagic fever, Uganda - update. Releve epidemiologique hebdomadaire/ Section dhygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/ Health Section of the Secretariat of the League of Nations. 2012;87:493
3. Outbreak news. Ebola haemorrhagic fever, Democratic Republic of the Congo. Releve epidemiologique hebdomadaire/ Section dhygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/ Health Section of the Secretariat of the League of Nations. 2012;87: 338-9
4. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009;2: 12-17
5. Ebihara H, Zivcec M, Gardner D, et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 2013;207:306-18
6. Safronetz D, Geisbert TW, Feldmann H. Animal models for highly pathogenic emerging viruses. Curr Opin Virol 2013;3: 205-9
7. Lupton HW, Lambert RD, Bumgardner DL, et al. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980;2:1294-5
8. Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002;8:503-7
9. Hoenen T, Groseth A, Feldmann H. Current ebola vaccines. Expert Opin Biol Ther 2012;12:859-72
10. Swenson DL, Warfield KL, Negley DL, et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005;23: 3033-42
11. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003;100:15889-94
12. Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005;175:1184-91
13. Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196(Suppl 2):S430-7
14. Warfield KL, Aman MJ. Advances in virus-like particle vaccines for filoviruses. J Infect Dis 2011;204(Suppl 3):S1053-9
15. Warfield KL, Posten NA, Swenson DL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007;196(Suppl 2): S421-9
16. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012;30(Suppl 5):F83-7
17. Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000;19:142-53
18. Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001;286:384-90
19. Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001;75:2660-4
20. Lee JS, Groebner JL, Hadjipanayis AG, et al. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006;24:6886-92
21. Herbert AS, Kuehne AI, Barth JF, et al. Venezuelan equine encephalitis replicon particle vaccine protects nonhuman primates from ebolavirus intramuscular and aerosol challenge. J Virol 2013; 87(9):4952-64
22. Reynard O, Mokhonov V, Mokhonova E, et al. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis 2011; 204(Suppl 3):S1060-5
23. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008;7:175-91
24. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998;246:134-44
25. Riemenschneider J, Garrison A, Geisbert J, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003;21: 4071-80
26. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006;13:1267-77
27. Grant-Klein RJ, Van Deusen NM, Badger CV, et al. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vaccin Immunother 2012;8(11): 1703-6
28. Shedlock DJ, Aviles J, Talbott KT, et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 2013;21: 1432-44
29. Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605-9
30. Aoki K, Barker C, Danthinne X, et al. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol Med 1999;5:224-31
31. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424:681-4
32. Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009;4:e5308
33. Richardson JS, Pillet S, Bello AJ, Kobinger GP. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 2013;87(7):3668-77
34. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010;28:950-7
35. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006;346:394-401
36. Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008;3:e3548
37. Richardson JS, Abou MC, Tran KN, et al. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis 2011; 204(Suppl 3):S1032-42
38. Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011;85:4222-33
39. Choi JH, Schafer SC, Zhang L. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm 2012;9:156-67
40. Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010;17:572-81
41. Roy S, Zhi Y, Kobinger GP, et al. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J Gen Virol 2006;87:2477-85
42. Zahn R, Gillisen G, Roos A, et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One 2012;7:e44115
43. Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008;15:460-7
44. Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010;6: e1000904
45. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010;29:304-13
46. Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011;17:1128-31
47. Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012;4:158ra46
48. Halfmann P, Kim JH, Ebihara H, et al. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci USA 2008;105: 1129-33
49. Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis 2011;204(Suppl 3):S986-90
50. Halfmann P, Ebihara H, Marzi A, et al. Replication-deficient ebolavirus as a vaccine candidate. J Virol 2009;83:3810-15
51. Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM, editor. Fields Virology. Lippincott Williams Wilkins, Philadelphia PA, USA; 2006. p. 2906-45
52. Gilligan JK GJ, Jahrling PB, Anderson K. Assessment of protective immunity conferred by recombinant vaccinia virus to guinea pigs challenged with ebola virus. In: BD, Brown FDoherty P, Mekalanos J, Norrby E, editor. Vaccines. cold spring harbor. Lanoratory Press, Cold Spring Habor, NY, USA; 1997. p. 87-92
53. Tsuda Y, Caposio P, Parkins CJ, et al. A replicating cytomegalovirus- based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 2011;5: e1275
54. Durbin AP, Skiadopoulos MH, McAuliffe JM, et al. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol 2000;74: 6821-31
55. Bukreyev A, Yang L, Zaki SR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006;80:2267-79
56. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007;81:6379-88
57. Bukreyev A, Marzi A, Feldmann F, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009;383:348-61
58. Bukreyev AA, Dinapoli JM, Yang L, et al. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 2010;399: 290-8
59. DiNapoli JM, Yang L, Samal SK, et al. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010;29:17-25
60. Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Scie U S A, 1995;92:4477-81
61. Marzi A, Feldmann H, Geisbert TW, Falzarano D. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef 2011; S1
62. Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 2012;6:e1567
63. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-49
64. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004;78:5458-65
65. Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007;196(Suppl 2):S404-12
66. Marzi A, Ebihara H, Callison J, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 2011;204(Suppl 3): S1066-74
67. Tsuda Y, Safronetz D, Brown K, et al. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis 2011;204(Suppl 3): S1090-7
68. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11: 786-90
69. Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 2009;4:e5547
70. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008;26:6894-900
71. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009;83:7296-304
72. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOVGP- mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013;110:1893-8
73. McGettigan JP, Pomerantz RJ, Siler CA, et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 2003;77:237-44
74. Blaney JE, Wirblich C, Papaneri AB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 2011;85: 10605-16
75. Papaneri AB, Wirblich C, Cann JA, et al. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology 2012;434:18-26
76. Papaneri AB, Wirblich C, Cooper K. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine 2012;30:6136-41
77. Blaney JE, Marzi A, Willet M, et al. Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013;9:e1003389